suppression up to the maximal degree does not improve the Maximal suppression of renin-angiotensin system in nonprolifantiproteinuric response and is coupled with a decrement of erative glomerulonephritis.
and, ultimately, damage at the tubulointerstitial level mL/min). The study was divided in three consecutive phases:
(1 ) four subsequent 1-month periods of ramipril at the dose [2, 3] . In nonproliferative glomerulonephritis (NPGN), of 2.5, 5.0, 10, and 20 mg/day; (2 ) 2 months of ramipril 20 mg/ the contribution of proteinuria to the pathophysiology of day ϩ irbesartan 300 mg/day; and (3 ) 2 months of irbesartan progression of renal damage is more prominent than in 300 mg/day alone.
proliferative glomerulopathies, where other factors play
Results. Maximizing RAS suppression was not coupled with a role [2] . Identification of the most effective antiproteinany major effect on renal function and blood pressure; conversely, a significant decrement in hemoglobin levels, of 0.8 g/dL uric treatment becomes therefore critical in NPGN.
on average, was observed during up-titration of ramipril dose.
In NPGN, the presence of nephrotic syndrome identiThe 2.5 mg dose of ramipril significantly decreased proteinuria fies the best candidates to immunosuppressive treatment; by 29%. Similar changes were detected after irbesartan alone however, this therapeutic intervention allows a complete (Ϫ28%). The antiproteinuric effect was not improved either by the higher ramipril doses (Ϫ30% after the 20 mg dose) or remission of proteinuria in about 50% of cases [4] [5] [6] . In to start such a treatment early in the course of disease, that is, prior to development of chronic renal failure [9] [10] [11] .
In this regard, we have recently evidenced in a small group of patients with moderate proteinuria due to proliferative glomerulonephritis (IgA nephropathy) that coadministration of angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II (Ang II) AT 1 receptor antagonist (ARA) decreases proteinuria by a greater exwas ramipril and angiotensin II AT 1 receptor (ARA) was irbesartan. The doses of the two agents were given in doses of mg/day. Basal tent (Ϫ63%) than the single agents alone (Ϫ35%) [12, 13] .
evaluation was performed at time 0.
The rationale for combination therapy is based on the assumption that ARA would counteract the AT 1 -mediated effects of Ang II formation by non-ACE enzymes while ACE-I would additionally increase kinins [14] .
the large number of visits and/or excessive distance of the hospital from their residence. Whether enhancement of RAS suppression allows a major antiproteinuric response in NPGN patients with modStudy design erate proteinuria is unknown.
In the present work, we studied NPGN patients with
This was an open-label study, performed on ambulatory basis, designed to compare prospectively the antinonnephrotic proteinuria and normal glomerular filtration rate (GFR). We monitored the antiproteinuric reproteinuric response to stepwise enhancement of RAS suppression with the patients' basal values as their own sponse during treatment with ramipril at doses progressively increased in a stepwise fashion, from 2.5 up to 20 control. The study lasted 14 months (Fig. 1) . Two months after withdrawal of eventual therapy with ACE-I or mg/day, then after adding irbesartan 300 mg/day to the maximal dose of ACE-I, and, finally, after irbesartan ARA (run in), patients underwent the clinical and biochemical basal evaluation and started the active treatalone. The study was aimed at evaluating whether in these patients the antiproteinuric response to ACE-I is ment protocol constituted by three consecutive phases:
(1) four subsequent 1-month periods of treatment with a dose-related phenomenon and add-on ARA enhances the antiproteinuric effect of maximized ACE inhibition.
ramipril at the dose of 2.5, 5.0, 10, and 20 mg/day; (2) 2 months of ramipril 20 mg/day ϩ irbesartan 300 mg/day; Since, in NPGN, renal prognosis is significantly worsened by the urinary excretion of proteins of low molecular and (3) 2 months of irbesartan 300 mg/day alone. Twomonth intervals of washout followed each phase. Study weight [15] [16] [17] , the so-called tubular proteinuria, we also evaluated the effect of maximal RAS suppression on the medication was administered twice a day (8:00 a.m. and 8:00 p.m.); in the study days, the morning dose was taken qualitative features of proteinuria.
after data collection at the outpatient clinic (between 8:00 and 9:00 a.m.). All patients were required to main-METHODS tain their usual salt intake throughout the period of the Patients study. We screened all adult patients followed in the outpaClinical and laboratory procedures tient renal clinic from December 1998 through December 2000 to select those who met the following enrollment Assessment of clinical and laboratory parameters was performed at baseline, at the end of each month of the criteria: biopsy-proven primary NPGN, moderate proteinuria (1.0 to 3.5 g/day), and serum albumin levels Ͼ3.0 first phase, at the end of the subsequent two phases, and at the end of each of the three washout periods. In addig/dL persisting for at least 12 months prior to the study in the absence of any immunosuppressive treatment and tion, to ensure the safety of the patients, serum creatinine and potassium, as well as blood pressure, were measured normal renal function (creatinine clearance Ͼ70 mL/min). We excluded patients with evidence of edema, diabetes between the 10th and the 15th day following any change of medication prescription. We measured at each step mellitus, renovascular disease, obstructive uropathy, serum potassium Ն5.5 mmol/L, cancer, chronic treatment proteinuria, urinary levels of ␣ 1 -microglobulin (␣ 1 m), creatinine, sodium (U Na V). and urea, as well as body weight, with anti-inflammatory drugs, and known or suspected intolerance to ACE-I or ARA.
blood pressure, serum creatinine, potassium, albumin, hemoglobin, peripheral plasma renin activity (PRA), Ten patients out of the 31 patients were found to be eligible in the 2-year period of screening and gave their and aldosterone. Blood pressure was measured in the morning before informed consent to enter onto the study. The remaining 21 eligible patients refused enrollment. The reasons they drug administration by a mercury sphygmomanometer after 10 minutes' rest. The first and fifth Korotkoff sounds gave included their fear of the potential side effects of the high-dose "antihypertensive" therapy or because of were used as systolic and diastolic blood pressure levels.
The mean of three consecutive measurements taken 2 molecular-weight (LMW) and the very low-molecularweight (VLMW) on the basis of the absence or presence minutes apart in the sitting position was used for statistical analysis. Mean blood pressure was calculated as the of protein bands with a molecular weight Ͻ23 kD, respectively. For the analysis of SDS-PAGE data, we assum of one third of systolic and two thirds of diastolic blood pressure. Blood pressure measurements were resigned a score to each pattern: VLMW ϭ 1, LMW ϭ 2, pure glomerular ϭ 3, physiologic ϭ 4; indeed, previous peated after 5 minutes in standing position to detect eventual orthostatic hypotension.
studies have demonstrated significant differences in terms of tubulointerstitial damage and renal prognosis among All the urinary samples were stored and analyzed at the same time. At each step, proteinuria was measured the four categories, with VLMW being characterized by the worst and physiologic by the best outcome [15, 16] . in two consecutive 24-hour urine collections (the mean value was recorded and used for statistical analysis) with Serum albumin, serum and urinary levels of creatinine, urea, sodium, and potassium were measured by an autothe pyrogallol red-molibdate method; the intra-assay and interassay coefficients of variation of this method was analyzer (Olympus AU 400, Olympus Italia, Segrate, Italy). Daily urea excretion was used to calculate protein less than 2%. The urinary levels of ␣ 1 m were assessed by immunonephelometric method on a Coulter Beckman intake as described in a previous paper by our group [18] . Hemoglobin was measured by Coulter counter (Coulter nephelometer, using caprine serum antihuman ␣ 1 m (Beckman, Fullerton, CA, USA). The intra-assay and interElectric, Hialeah, FL, USA). PRA and aldosterone were measured by a radioimmunoassay (RIA) technique usassay coefficients of variation of this method was less than 5%.
ing commercial kits (DPC, Los Angeles, CA, USA). The pattern of urinary proteins was determined at Statistics baseline, and at the end of the three phases (uptitration of ramipril dose, combined treatment, and irbesartan
Results are reported as mean Ϯ SD. Analysis of variance for repeated measures was always applied to comalone) by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), as previously described pare arms, using pretreatment values as covariates when appropriate. With only two groups to be compared that [15] . The Mini-Protean II apparatus (Bio-Rad Laboratories, Hercules, CA, USA) was used. Urine samples analysis reduces to a paired t test. Focus was on the following predefined questions: (1) Do the three differ-(the volume ranged from 2 to 19 L to apply a protein amount of 3.5 g) were applied to polyacrylamide gel ent treatments (ACE-I, ARA, ACE-I ϩ ARA) have any effect on pre-treatment values? (2) Is there a dose slab (85 ϫ 70 ϫ 1 mm, 12% of acrylamide/N,N'-methylene bis-acrylamide, 30% weight/volume). Electrophoreeffect of ACE-I treatment? (3) Is the effect of ACE-I ϩ ARA greater than that of single agents? Since treatments sis was programmed to run at 60 volts for stacking and 110 volts for running layer of slabs in discontinuous runwere assigned sequentially and a carryover bias could possibly confound results, a washout period of 2 months ning buffer, using the Bio-Rad Power Supply Model 200/ 2.0 apparatus (Bio-Rad Laboratories). The gels were was planned among the different treatments; therefore, similarity of pretreatment conditions was preliminarily stained with Coomassie blue R 250 (which produces blue protein bands with sensitivity as low as 8 to 28 ng) for 30 tested to exclude a carryover effect. A period effect could not be tested; indeed, we could not randomize the type minutes at room temperature; subsequently, they were distained with an acetic acid/methanol/aqueous solution of treatment because administration of either ACE-I at high dose or combined treatment without preliminary (1:5:4 volume) to give sufficiently clear background and fixed between two cellophane papers and dried. The evaluation of the effects of ACE-I at lower doses would have been unethical in our normotensive patients. Fimolecular weight of urinary protein bands was assessed by comparison with standard protein of known molecular nally, to test whether the antiproteinuric effect of treatment was mediated by the blood pressure lowering efweight (10 kD Protein Ladder; GIBCO BRL, Uxbridge, UK), using Ultrascan XL 2222 Densitometer (Pharmacia fect, the pre-and posttreatment values of proteinuria were analyzed using the respective values of blood pres-LKB Biotechnology AB, Uppsala, Sweden). The SDS-PAGE patterns are classified according to the presence sure (systolic, diastolic, and mean) as covariates. We also estimated correlation coefficients between changes in of protein bands of different molecular weights [15, 16] . Specifically, the pattern characterized by the albumin proteinuria and concomitant changes in systolic blood pressure, diastolic blood pressure and mean blood presband alone (68 kD) is considered "physiologic," while the presence, beside albumin, of protein bands of molecsure. Two-tailed significance level was 0.05. A sample size of ten patients adequately allowed an ular weight Ͼ68 kD identifies the "pure glomerular" pattern. A "tubular" pattern is defined by the presence, average power of 89% (range, 80% to 95% depending on the number of groups compared) to detect a difference in beside albumin and proteins with molecular weight Ͼ68, of protein bands with molecular weight Ͻ68 kD; specifimeans across the levels of repeated measures factor equal to half of the common standard deviation, that is, cally, two tubular patterns can be distinguished: the low- an effect size of 0.5 at a significance level of 0.05 (nQuery ACE-I versus pretreatment conditions was observed for systolic blood pressure (P ϭ 0.0001), diastolic blood presAdvisor 1.0, 1995).
sure (P ϭ 0.0007), mean blood pressure (P ϭ 0.0002), PRA (P ϭ 0.001), aldosterone (P ϭ 0.04), and hemoglo-RESULTS bin (P ϭ 0.05). We studied two females and eight males with a mean ACE-I treatment significantly affected proteinuria age of 34 years old (range, 21 to 51 years). The histologic (P ϭ 0.0005) and ␣ 1 m (P ϭ 0.03). At baseline, proteinuria diagnosis was idiopathic membranous nephropathy (N ϭ averaged 2.55 Ϯ 0.94 g/day (range, 1.1 to 3.2 g/day). The 5) and primary focal segmental glomerulosclerosis (N ϭ 5).
decrement of proteinuria during ACE-I was equal to Seven of the patients studied had been previously treated 30% on average, with the lowest dose of ramipril (2.5 mg/day) inducing a 29% reduction. with immunosuppressive therapy (steroids alone or in combination with cyclophosphamide). At baseline, body Dose-effect of ACE-I weight was 69.3 Ϯ 10 kg and serum albumin was 3.8 Ϯ A statistically significant effect of the different doses 0.6 g/dL; these values did not change throughout the of ramipril (from 2.5 up to 20 mg/day) was observed for different steps. Similarly, protein intake, that averaged PRA that increased from 4.2 to 7.1 ng/mL/hour (P ϭ 1.14 Ϯ 0.12 g/kg body weight/day at baseline, did not 0.004), aldosterone that decreased from 80 to 44 pg/mL vary subsequently.
(P ϭ 0.006), ␣ 1 m that decreased from 26.0 to 19.2 mg/ We did not detect in any patient, at any step, either day (P ϭ 0.04), and hemoglobin that decreased from acute renal failure (that is, an increment of serum creati-14.6 to 13.8 g/dL (P ϭ 0.003). Conversely, no difference nine Ͼ30% versus pretreatment values), or hyperkaamong the different doses of ACE-I was observed for lemia (that is, serum K Ն5.5 mmol/L). No symptomatic proteinuria (P ϭ 0.94), systolic blood pressure (P ϭ hypotensive episodes, dizziness, or fatigue were observed 0.72), diastolic blood pressure (P ϭ 0.62), and mean throughout the study.
blood pressure (P ϭ 0.64). The same held true for creatiThe main clinical and biochemical features of patients nine clearance, serum potassium, and U NA V. according to the type of treatment are summarized in Table 1 , with the exception of proteinuria and ␣ 1 m excreEffect of ARA treatment tion that have been reported in Figure 2 .
No difference was observed for creatinine clearance, serum potassium, U NA V, aldosterone, and hemoglobin, Carryover effect while a significant effect of ARA versus pretreatment No difference was found across the pretreatment valconditions was observed for Uprot (P ϭ 0.003) that deues (baseline and washout periods) of the parameters creased by 28%, ␣ 1 m (P ϭ 0.04), systolic blood pressure examined, testifying that basal conditions were always (P ϭ 0.003), diastolic blood pressure (P ϭ 0.01), mean restored after washout periods.
blood pressure (P ϭ 0.003), and PRA (P ϭ 0.0005).
Effect of ACE-I treatment
Effect of combination ACE-I ϩ ARA No difference was detected for creatinine clearance, A significant effect of combination versus pretreatment conditions was observed for proteinuria (P ϭ 0.0009), serum potassium, and U Na V, while a significant effect of A significant difference among the three arms was observed only for PRA (P ϭ 0.01), aldosterone (P ϭ 0.005), and hemoglobin (P ϭ 0.02). Conversely, no difference was lar, the pattern was LMW in six and VLMW in four noted for proteinuria (P ϭ 0.94), that decreased by 33% patients (Table 2) . At the end of up-titration of ramipril in the combination arm, ␣ 1 m (P ϭ 0.33), systolic blood dose, the pattern changed from VLMW to LMW in three pressure (P ϭ 0.46), diastolic blood pressure (P ϭ 0.80), patients, and from LMW to physiologic in one patient. and mean blood pressure (P ϭ 0.62). The same held true No further change was detected in the subsequent steps for serum potassium, creatinine clearance, and U Na V.
with the exception of a shift from LMW to pure glomeruRelationship between antiproteinuric and blood lar pattern in one patient at the end of the study. The pressure lowering effect amelioration of pattern was testified by the significant increase of score. After adjustment by values of blood pressure (systolic, diastolic, and mean), the mean values of proteinuria did not significantly vary during ramipril 2.5 mg/day (from DISCUSSION an unadjusted decrease of 0.8 g/day to values of 0.7 g/day
In NPGN, previous studies have evaluated the antiproadjusted for systolic, diastolic, and mean blood presteinuric effect of either increasing the dosage of ACE-I/ sures). Similar results were obtained when considering ARA [19] [20] [21] [22] [23] , or combining the two agents [23, 24] . In the higher doses of ramipril, combined treatment, and all these studies, however, patients were characterized irbesartan alone. Accordingly, no significant correlation by nephrotic proteinuria and renal dysfunction, that is, was found between the percentual changes of proteinuria features that usually indicate prescription of immunoand systolic, diastolic, and mean blood pressures. suppressive treatment; a reduction of proteinuria below Effects of treatments on pattern of proteinuria the nephrotic range was in fact hardly achieved. The current work is the first study that addresses the question In basal conditions, all the patients showed a tubular pattern of proteinuria at SDS-PAGE analysis; in particuas whether enhancement of RAS suppression amelio-rates the antiproteinuric response in NPGN patients with (Fig. 2) , despite the presence of a stepwise elevation in PRA values. Of note, the results of the current study moderate proteinuria and preserved renal function that are usually treated with symptomatic therapy. Suppression actually differ from what has been reported in nondiabetic glomerulopathies characterized by expansion of of RAS was pushed up to the maximal degree by stepwise increase of ramipril dosage from 2.5 up to 20 mg/day, mesangial area. Similarly to IgA nephropathy, in fact, also in NPGN patients with nephrotic syndrome either that is, a dose four-fold greater than the maximal dosage of the REIN study [11] , followed by add-on treatment the increase of the dose of ACE-I/ARA or the coadministration of the two agents allow a greater decrement of with 300 mg/day of irbesartan, that is, the maximal dose used currently in clinical trials [25] . This two-phase analyproteinuria [19] [20] [21] [22] [23] [24] . On the basis of these findings, it is reasonable to hypothesize that after enhancing RAS sis is essential to verify the presence of additive effects of the combination therapy since both agents act of the same suppression a larger antiproteinuric effect may become manifest only in the presence of significant mesangial system. Indeed, Agarwal [26] has recently demonstrated in diabetic patients with chronic renal failure the absence expansion secondary to mesangium overload, as in the presence of severe proteinuria, or primarily caused by of any specific advantage of adding ARA on top of ACE-I when the latter is administered at high dose. Conversely, the underlying disease, as in the case of IgA nephropathy. Indeed, proliferation of mesangial cells is associated in most of the studies published to date on the antiproteinuric effect of combined therapy in both proliferative with high sensitivity to the beneficial effects of ACE-I and ARA on glomerular structure and function [30]; and NPGN, the impact of ACE-I ϩ ARA has been tested without preliminary evaluation of the effects of on the other hand, the glomerular response to Ang II disappears after mesangial cell lysis [31] . This hypothesis ACE-I at doses higher than usual.
All the ramipril doses administered and the combinamay therefore account for the lack of a greater antiproteinuric effect in response to maximized RAS supprestion therapy were well tolerated and not associated with significant side effects. Of note, however, hemoglobin levsion in our NPGN patients with moderate proteinuria. In our patients, we had to maintain a normal salt intake els tended to diminish when ramipril dose was increased, with the maximal reduction of 0.8 g/dL on average, debecause of the optimal blood presssure levels detected prior to the study; consequently, we cannot exclude that tected after administration of the 20 mg dose. On the contrary, no hemoglobin change was noted after admina larger antiproteinuric effect of maximal RAS suppression would have been attained at low sodium diet [19, 23] . istration of irbesartan alone. The class-specific lowering effect of ACE-I on hemoglobin levels, recently reported Furthermore, this trial was designed to assess the shortterm antiproteinuric response to a stepwise enhancement also in renal transplant recipients [27] , has been ascribed to the reduced degradation of a physiologic inhibitor of of RAS suppression; therefore, we cannot exclude that the higher doses of ramipril or add-on ARA treatment erythropoiesis [28] . The clinical implication of these data may not be trivial because even a 0.5 g/dL decrement may allow a more favorable outcome of renal function in the long-term. Nevertheless, the short-term antiproof hemoglobin levels is associated with significant growth of left ventricular mass in patients with anemia secondary teinuric response achieved by the low doses of ACE-I or ARA can be reasonably considered as already preto chronic renal failure [29] .
Ramipril induced a reduction of proteinuria, of about dictive of a more benign course [1, 9-11].
Our clinical study was not primarily designed to inves-30% on average (Fig. 2) , in the absence of changes of creatinine clearance and salt intake. The 2.5 mg/day dose tigate on the mechanism(s) of the antiproteinuric response to RAS suppression; indeed, previous studies in of ramipril was sufficient to determine this effect, and a similar reduction was observed after irbesartan alone.
nondiabetic patients with nephrotic syndrome have addressed this issue, showing that either standard or higher Restoration of proteinuria to basal values in the washout periods demonstrates that the positive results on protein-ACE-I doses induce a specific improvement of glomerular barrier size-selective dysfunction independently from uria were not achieved by chance or dependent on spontaneous remission of underlying disease. The extent of the antihypertensive effect [20, 22, 32] . In the present work, blood pressure decreased of about 10% after the the antiproteinuric response to the usual doses of ACE-I or ARA is analogous to that we have previously ob-2.5 mg dose of ramipril, and, by the same extent, after irbesartan with no further decrement in response to higher served in a small group of patients with similar characteristics (moderate proteinuria, normal GFR, and blood ACE-I doses or to add-on ARA. Nevertheless, analysis of covariance and the absence of any correlation between pressure) but with IgA nephropathy [12, 13] .
However, at variance with our previous studies [12, 13] , the changes of proteinuria and of blood pressure suggest that the decrease of proteinuria was largely independent in the current work no improvement of the antiproteinuric effect was evidenced after enhancing RAS suppresfrom the changes of systemic blood pressure. Further novel insights into the antiproteinuric response sion; in fact, neither the increase of ramipril dose nor add-on ARA led to additional decrement of proteinuria to RAS suppression were obtained when evaluating the
